Literature DB >> 36156185

Toward More Accessible Fully Automated 3D Volumetric MRI Decision Trees for the Differential Diagnosis of Multiple System Atrophy, Related Disorders, and Age-Matched Healthy Subjects.

Jisoo Kim1, Geoffrey S Young1, Andrew S Willett2, Ariana T Pitaro2, Grace F Crotty2,3, Merlyne Mesidor2, Kristie A Jones2, Camden Bay1, Min Zhang1, Mel B Feany4, Xiaoyin Xu1, Lei Qin1,5, Vikram Khurana6,7,8,9.   

Abstract

Differentiating multiple system atrophy (MSA) from related neurodegenerative movement disorders (NMD) is challenging. MRI is widely available and automated decision-tree analysis is simple, transparent, and resistant to overfitting. Using a retrospective cohort of heterogeneous clinical MRIs broadly sourced from a tertiary hospital system, we aimed to develop readily translatable and fully automated volumetric diagnostic decision-trees to facilitate early and accurate differential diagnosis of NMDs. 3DT1 MRI from 171 NMD patients (72 MSA, 49 PSP, 50 PD) and 171 matched healthy subjects were automatically segmented using Freesurfer6.0 with brainstem module. Decision trees employing substructure volumes and a novel volumetric pons-to-midbrain ratio (3D-PMR) were produced and tenfold cross-validation performed. The optimal tree separating NMD from healthy subjects selected cerebellar white matter, thalamus, putamen, striatum, and midbrain volumes as nodes. Its sensitivity was 84%, specificity 94%, accuracy 84%, and kappa 0.69 in cross-validation. The optimal tree restricted to NMD patients selected 3D-PMR, thalamus, superior cerebellar peduncle (SCP), midbrain, pons, and putamen as nodes. It yielded sensitivities/specificities of 94/84% for MSA, 72/96% for PSP, and 73/92% PD, with 79% accuracy and 0.62 kappa. There was correct classification of 16/17 MSA, 5/8 PSP, 6/8 PD autopsy-confirmed patients, and 6/8 MRIs that preceded motor symptom onset. Fully automated decision trees utilizing volumetric MRI data distinguished NMD patients from healthy subjects and MSA from other NMDs with promising accuracy, including autopsy-confirmed and pre-symptomatic subsets. Our open-source methodology is well-suited for widespread clinical translation. Assessment in even more heterogeneous retrospective and prospective cohorts is indicated.
© 2022. The Author(s).

Entities:  

Keywords:  Atypical parkinsonism; MSA; PD; PSP; Volumetric analysis

Year:  2022        PMID: 36156185     DOI: 10.1007/s12311-022-01472-7

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.648


  35 in total

1.  A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.

Authors:  Aldo Quattrone; Maurizio Morelli; Salvatore Nigro; Andrea Quattrone; Basilio Vescio; Gennarina Arabia; Giuseppe Nicoletti; Rita Nisticò; Maria Salsone; Fabiana Novellino; Gaetano Barbagallo; Emilio Le Piane; Pierfrancesco Pugliese; Domenico Bosco; Maria Grazia Vaccaro; Carmelina Chiriaco; Umberto Sabatini; Virginia Vescio; Carlo Stanà; Federico Rocca; Domenico Gullà; Manuela Caracciolo
Journal:  Parkinsonism Relat Disord       Date:  2018-07-25       Impact factor: 4.891

2.  Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.

Authors:  Demetrio Messina; Antonio Cerasa; Francesca Condino; Gennarina Arabia; Fabiana Novellino; Giuseppe Nicoletti; Maria Salsone; Maurizio Morelli; Pier Luigi Lanza; Aldo Quattrone
Journal:  Parkinsonism Relat Disord       Date:  2011-01-13       Impact factor: 4.891

3.  PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.

Authors:  Tomoko Kurata; Satsuki Kametaka; Yasuyuki Ohta; Nobutoshi Morimoto; Shoko Deguchi; Kentaro Deguchi; Yoshio Ikeda; Yoshiki Takao; Taisei Ohta; Yasuhiro Manabe; Shuhei Sato; Koji Abe
Journal:  Intern Med       Date:  2011-11-15       Impact factor: 1.271

4.  Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy.

Authors:  Salvatore Nigro; Gennarina Arabia; Angelo Antonini; Luca Weis; Andrea Marcante; Alessandro Tessitore; Mario Cirillo; Gioacchino Tedeschi; Stefano Zanigni; Giovanna Calandra-Buonaura; Caterina Tonon; Gianni Pezzoli; Roberto Cilia; Mario Zappia; Alessandra Nicoletti; Calogero Edoardo Cicero; Michele Tinazzi; Pierluigi Tocco; Nicolò Cardobi; Aldo Quattrone
Journal:  Eur Radiol       Date:  2016-10-19       Impact factor: 5.315

5.  Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism.

Authors:  Beatrice Heim; Stephanie Mangesius; Florian Krismer; Gregor K Wenning; Anna Hussl; Christoph Scherfler; Elke R Gizewski; Michael Schocke; Regina Esterhammer; Andrea Quattrone; Werner Poewe; Klaus Seppi
Journal:  Parkinsonism Relat Disord       Date:  2020-11-24       Impact factor: 4.891

6.  New and reliable MRI diagnosis for progressive supranuclear palsy.

Authors:  H Oba; A Yagishita; H Terada; A J Barkovich; K Kutomi; T Yamauchi; S Furui; T Shimizu; M Uchigata; K Matsumura; M Sonoo; M Sakai; K Takada; A Harasawa; K Takeshita; H Kohtake; H Tanaka; S Suzuki
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

7.  MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.

Authors:  Aldo Quattrone; Giuseppe Nicoletti; Demetrio Messina; Francesco Fera; Francesca Condino; Pierfrancesco Pugliese; Pierluigi Lanza; Paolo Barone; Letterio Morgante; Mario Zappia; Umberto Aguglia; Olivier Gallo
Journal:  Radiology       Date:  2007-11-08       Impact factor: 11.105

8.  The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.

Authors:  Luke A Massey; Hans R Jäger; Dominic C Paviour; Sean S O'Sullivan; Helen Ling; David R Williams; Constantinos Kallis; Janice Holton; Tamas Revesz; David J Burn; Tarek Yousry; Andrew J Lees; Nick C Fox; Caroline Micallef
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

9.  Clinical Milestones Preceding the Diagnosis of Multiple System Atrophy and Progressive Supranuclear Palsy: A Retrospective Cohort Study.

Authors:  Louise Wiblin; Rory Durcan; Brook Galna; Mark Lee; David Burn
Journal:  J Mov Disord       Date:  2019-08-09

10.  Progressive Supranuclear Palsy with Predominant Cerebellar Ataxia.

Authors:  Shoichiro Ando; Masato Kanazawa; Osamu Onodera
Journal:  J Mov Disord       Date:  2019-12-19
View more
  1 in total

1.  Clinical Trial-Ready Patient Cohorts for Multiple System Atrophy: Coupling Biospecimen and iPSC Banking to Longitudinal Deep-Phenotyping.

Authors:  Alain Ndayisaba; Ariana T Pitaro; Andrew S Willett; Kristie A Jones; Claudio Melo de Gusmao; Abby L Olsen; Jisoo Kim; Eero Rissanen; Jared K Woods; Sharan R Srinivasan; Anna Nagy; Amanda Nagy; Merlyne Mesidor; Steven Cicero; Viharkumar Patel; Derek H Oakley; Idil Tuncali; Katherine Taglieri-Noble; Emily C Clark; Jordan Paulson; Richard C Krolewski; Gary P Ho; Albert Y Hung; Anne-Marie Wills; Michael T Hayes; Jason P Macmore; Luigi Warren; Pamela G Bower; Carol B Langer; Lawrence R Kellerman; Christopher W Humphreys; Bonnie I Glanz; Elodi J Dielubanza; Matthew P Frosch; Roy L Freeman; Christopher H Gibbons; Nadia Stefanova; Tanuja Chitnis; Howard L Weiner; Clemens R Scherzer; Sonja W Scholz; Dana Vuzman; Laura M Cox; Gregor Wenning; Jeremy D Schmahmann; Peter Novak; Geoffrey S Young; Mel B Feany; Tarun Singhal; Vikram Khurana
Journal:  Cerebellum       Date:  2022-10-03       Impact factor: 3.648

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.